LY-517717

DB05713InvestigationalSmall molecule

LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

Mechanism: LY517717, an investigational oral direct inhibitor of activated Factor Xa, appears to interrupt thrombus formation without impairing platelet hemostatic function.
Curator reviewed
Primary indication: Investigated for use/treatment in thrombosis and venous thromboembolism.Curator reviewed
Formula / weight: C₂₇H₃₃N₅O₂ · 459.594 g/mol (avg)
Code names: LY-517717

Resolves to

Compound

Structure

InChIKeyVYNKVNDKAOGAAQ-RUZDIDTESA-NSMILESCN1CCC(CC1)N1CCN(CC1)C(=O)[C@H](NC(=O)C1=CC=C2C=CNC2=C1)C1=CC=CC=C1

Targets

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with LY-517717, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.